Maraviroc: a CCR5 antagonist. (March 2008)

• Record Type: Journal Article
• Authors: Tan, LKK; Nelson, M
• Is Part Of: Future HIV therapy. Volume 2:Number 2(2008)
• Page Start: 111
• Page End: 123
• Publication Date: 2008-03
• Subjects: CCR5 antagonist -- HIV-1 -- maraviroc -- viral tropism; HIV (Viruses) -- Treatment -- Periodicals; HIV (Viruses) -- Research -- Periodicals; 616.979206
• DOI: 10.2217/17469600.2.2.111
• Languages: English
• ISSNs: 1746-9600

Abstract

HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48 weeks, has been shown to be efficacious as part of an optimized antiretroviral regimen against CCR5 tropic HIV-1 in treatment-experienced patients. A further trial has demonstrated its noninferiority to efavirenz in achieving a HIV viral load less than 400 copies/ml as part of highly active antiretroviral therapy in treatment-naive individuals. It has recently received regulatory approval for use in North America and Europe in treatment-experienced patients. With increasing use, the role of maraviroc in the treatment of HIV-infected patients will be more clearly defined.